Literature DB >> 30559465

Dementia with Lewy bodies - from scientific knowledge to clinical insights.

Nikitas A Arnaoutoglou1, John T O'Brien2, Benjamin R Underwood3,4.   

Abstract

Dementia with Lewy bodies (DLB) is the underlying aetiology of 10-15% of all cases of dementia and as such is a clinically important diagnosis. In the past few years, substantial advances have been made in understanding the genetics and pathology of this condition. For example, research has expanded our knowledge of the proteinaceous inclusions that characterize the disease, has provided an appreciation of the role of disease-associated processes such as inflammation and has revealed an association between DLB and genes such as GBA. These insights might have broader relevance to other neurodegenerative conditions and are beginning to be translated into clinical trials. In this Review, we provide clinical insights for the basic scientist and a basic science foundation for the clinician. We discuss the history of the condition; the definition of DLB; the relationship between DLB and other neurodegenerative conditions; current understanding of the pathology, genetics, clinical presentation and diagnosis of DLB; options for treatment; and potential future directions for research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30559465     DOI: 10.1038/s41582-018-0107-7

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  136 in total

1.  An essay on the shaking palsy. 1817.

Authors:  James Parkinson
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2002       Impact factor: 2.198

2.  Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia).

Authors:  W R Gibb; M M Esiri; A J Lees
Journal:  Brain       Date:  1987-10       Impact factor: 13.501

Review 3.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Authors:  I G McKeith; D Galasko; K Kosaka; E K Perry; D W Dickson; L A Hansen; D P Salmon; J Lowe; S S Mirra; E J Byrne; G Lennox; N P Quinn; J A Edwardson; P G Ince; C Bergeron; A Burns; B L Miller; S Lovestone; D Collerton; E N Jansen; C Ballard; R A de Vos; G K Wilcock; K A Jellinger; R H Perry
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

4.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

5.  Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease?

Authors:  K Kosaka; M Yoshimura; K Ikeda; H Budka
Journal:  Clin Neuropathol       Date:  1984 Sep-Oct       Impact factor: 1.368

6.  The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity.

Authors:  L Hansen; D Salmon; D Galasko; E Masliah; R Katzman; R DeTeresa; L Thal; M M Pay; R Hofstetter; M Klauber
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

7.  In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies.

Authors:  Z Walker; D C Costa; P Ince; I G McKeith; C L Katona
Journal:  Lancet       Date:  1999-08-21       Impact factor: 79.321

8.  Neuroleptic sensitivity in patients with senile dementia of Lewy body type.

Authors:  I McKeith; A Fairbairn; R Perry; P Thompson; E Perry
Journal:  BMJ       Date:  1992-09-19

9.  Presenile dementia with Alzheimer-, Pick- and Lewy-body changes.

Authors:  K Kosaka; S Oyanagi; M Matsushita; A Hori
Journal:  Acta Neuropathol       Date:  1976-11-15       Impact factor: 17.088

10.  Operational criteria for senile dementia of Lewy body type (SDLT).

Authors:  I G McKeith; R H Perry; A F Fairbairn; S Jabeen; E K Perry
Journal:  Psychol Med       Date:  1992-11       Impact factor: 7.723

View more
  15 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 2.  Neuroscience robotics for controlled induction and real-time assessment of hallucinations.

Authors:  Fosco Bernasconi; Eva Blondiaux; Giulio Rognini; Herberto Dhanis; Laurent Jenni; Jevita Potheegadoo; Masayuki Hara; Olaf Blanke
Journal:  Nat Protoc       Date:  2022-09-12       Impact factor: 17.021

3.  α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice.

Authors:  Yemima R Butler; Yuqing Liu; Ramhari Kumbhar; Peiran Zhao; Kundlik Gadhave; Ning Wang; Yanmei Li; Xiaobo Mao; Wenjing Wang
Journal:  Nat Commun       Date:  2022-07-19       Impact factor: 17.694

4.  Overcoming blood-brain barrier transport: Advances in nanoparticle-based drug delivery strategies.

Authors:  Shichao Ding; Aminul Islam Khan; Xiaoli Cai; Yang Song; Zhaoyuan Lyu; Dan Du; Prashanta Dutta; Yuehe Lin
Journal:  Mater Today (Kidlington)       Date:  2020-03-04       Impact factor: 31.041

Review 5.  Differentiating dementia with Lewy bodies from Alzheimer's disease and Parkinson's disease dementia: an update on imaging modalities.

Authors:  Rotem Iris Orad; Tamara Shiner
Journal:  J Neurol       Date:  2021-01-29       Impact factor: 4.849

Review 6.  The Cryo-EM Effect: Structural Biology of Neurodegenerative Disease Aggregates.

Authors:  Benjamin C Creekmore; Yi-Wei Chang; Edward B Lee
Journal:  J Neuropathol Exp Neurol       Date:  2021-06-04       Impact factor: 3.148

7.  Nonsense-mediated mRNA decay factor UPF1 promotes aggresome formation.

Authors:  Yeonkyoung Park; Joori Park; Hyun Jung Hwang; Byungju Kim; Kwon Jeong; Jeeyoon Chang; Jong-Bong Lee; Yoon Ki Kim
Journal:  Nat Commun       Date:  2020-06-19       Impact factor: 14.919

8.  Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease.

Authors:  Sara Hall; Shorena Janelidze; Elisabet Londos; Antoine Leuzy; Erik Stomrud; Jeffrey L Dage; Oskar Hansson
Journal:  Mov Disord       Date:  2020-12-07       Impact factor: 10.338

9.  Sleep Disturbances and Associated Factors in Drug-Naïve Patients with Parkinson's Disease.

Authors:  Min Zhong; Xu Jiang; Sha Zhu; Ruxin Gu; Yu Bai; Hong He; Yang Pan; Pingyi Xu; Jun Yan; Li Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2021-12-03       Impact factor: 2.570

10.  An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB).

Authors:  Frederick M Lang; Daniel Y Kwon; Dag Aarsland; Brad Boeve; Babak Tousi; Mark Harnett; Yi Mo; Marwan Noel Sabbagh
Journal:  Alzheimers Dement (N Y)       Date:  2021-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.